Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1b Clinical study of BXCL501 in combination with duloxetine for Major Depressive Disorder in healthy subjects

Next Previous
X
Search
Trial Profile

Phase 1b Clinical study of BXCL501 in combination with duloxetine for Major Depressive Disorder in healthy subjects

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 May 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dexmedetomidine (Primary) ; Duloxetine (Primary)
  • Indications Major depressive disorder
  • Focus Adverse reactions

    • Most Recent Events

    • 21 May 2024 According to a BioXcel Therapeutics media release, results from this trial will be presented at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting.
    • 16 May 2023 Primary endpoint (Pharmacokinetics) has been met, according to a BioXcel Therapeutics media release.
    • 16 May 2023 According to a BioXcel Therapeutics media release, the company plans to present results from the Phase 1b MAD study at an upcoming medical conference.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top